Preferred Label : t(9;22)(q34.1;q11)(ABL1,BCR) fusion transcript/control transcript:LnRto:Pt:Bone mar:Qn:Molgen;
LOINC status : ACTIVE;
LOINC display name : t(9;22)(q34.1;q11)(ABL1,BCR) fusion transcript/control transcript Molgen (BM) [Log
# ratio];
LOINC long common name : t(9;22)(q34.1;q11)(ABL1,BCR) fusion transcript/control transcript [Log Number Ratio]
in Bone marrow by Molecular genetics method;
LOINC short name : t(9;22)(ABL1,BCR)/control Mar-LnRto;
LOINC description : The level of fusion gene transcript in the test sample is expressed as a log reduction;
i.e., log10 of the ratio of chimeric BCR-ABL/normal ABL mRNA transcript seen in individuals
with untreated CML (Chronic Myelogenous Leukemia) as compared to the ratio seen in
the patient. In Quest's laboratory data, the median of BCR-ABL/ABL Ratio in previously
untreated CML patients is 4.1325 in peripheral blood samples (N 120) and 5.09 in bone
marrow samples (N 109). Based on the IRIS study (New England Journal of Medicine,
2003, 3349:1423-1432), it is not necessary to know the BCR-ABL:ABL ratio of a patient
at baseline to calculate the subsequent change and this calculation should be based
on the above-mentioned median. Based on this study, a 3 log of higher reduction by
12 months of therapy is associated with negligible risk of disease progression during
the subsequent 12 months with patients are treated with imatinib. The following formula
is used for calculating log reduction by Quest Laboratories: LOG10(4.1325)-LOG10 (BCR-ABL:ABL
ratio) Unit/Log Reduction. Information from Quest Diagnostics. 2006 12 06.;
Origin ID : 82905-1;
UMLS CUI : C4298357;
Has component
- Has method
- Has property
- Has system
- Has time aspect
- Semantic type(s)
